The defining event of Moderna's second quarter was a deliberate rotation of the equity story away from a single-pandemic-product past and toward a multi-product respiratory, oncology, and rare disease future. Total revenue came in at $145 million, up just 2% year-over-year. Net product sales fell 18% on continued erosion of U.S. and South American COVID demand, while other revenue grew 82% on stand-ready manufacturing fees and a new Recordati collaboration for the propionic acidemia therapeutic. The narrative driver is not the headline number but the catalog of pipeline catalysts that landed during the quarter. In April, the European Commission authorized mCOMBRIAX, the flu plus COVID combination shot, for adults 50 and older. In June, the FDA's VRBPAC voted unanimously that mRNA-1010's benefits outweigh its risks for older adults. At ASCO, the five-year Phase 2b readout for intismeran plus KEYTRUDA showed a sustained 49% reduction in recurrence or death versus KEYTRUDA alone in adjuvant melanoma. The registrational study of mRNA-3927 in propionic acidemia also reached target enrollment in the period. The pull on attention this quarter was less about operating leverage and more about whether the platform can convert regulatory and clinical events into revenue beyond the legacy Spikevax franchise.
Shares trade near $151. The fifty-two week range runs from $22.28 to $176.66. The market capitalization is close to $60 billion on roughly 399 million shares outstanding. Average daily volume sits near 15 million shares with low beta. The valuation sits far above book on an accounting basis because the balance sheet holds $6.9 billion of cash and investments. The share price has traveled from a fifty-two week low near the mid-twenties to a recent peak above $150 in roughly twelve months. That trajectory tells the reader the equity is being priced for an inflection rather than marked to current revenue. Whether that inflection actually arrives is the central debate, and the rest of the report builds the evidence on each side.
The strongest counterargument to the bull case is that the operating losses remain large. The second-quarter net loss came in at $782 million, and the half-year net loss reached $2.1 billion. The cost of sales line is artificially swollen by $884 million of Arbutus and Genevant litigation royalty and intangible amortization booked in the first six months. Excluding that one-time hit, the underlying cost base is shrinking. The principal forward variable to monitor is the mRNA-1010 PDUFA decision. The FDA assigned August 5, 2026 as the goal date. The expected Phase 3 adjuvant melanoma data for intismeran reads out later this year. The mRNA-3927 readout in propionic acidemia and the speed of European mCOMBRIAX uptake round out the calendar. Investors paying tens of billions for the equity are buying optionality on those data points and on the platform's ability to monetize mRNA beyond Spikevax.